In Phase 2 Trial, Neflamapimod Aids Cognition in Lewy Body Dementia
After missing primary endpoints in Alzheimer’s trials, this p38 MAPKa inhibitor gained some traction in a test in people with DLB.
46 RESULTS
Sort By:
After missing primary endpoints in Alzheimer’s trials, this p38 MAPKa inhibitor gained some traction in a test in people with DLB.